1527-3350/asset/cover.gif?v=1&s=3cd983af6575c8dbfd6b47a63ffa95415ace15f8 "Hepatology")
fax: 858-527-1540
1527-3350/asset/olbannerleft.gif?v=1&s=4b2409f9534ed500d3c8da1940a23842e2b9932d)
1527-3350/asset/olbannerright.gif?v=1&s=141b9a8485298533c3e2016e937b0404f7d933e1)
Viral Hepatitis
You have full text access to this OnlineOpen article
Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection†
Article first published online: 22 AUG 2005
DOI: 10.1002/hep.20839
Copyright © 2005 American Association for the Study of Liver Diseases
Additional Information
How to Cite
Horsmans, Y., Berg, T., Desager, J.-P., Mueller, T., Schott, E., Fletcher, S. P., Steffy, K. R., Bauman, L. A., Kerr, B. M. and Averett, D. R. (2005), Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology, 42: 724–731. doi: 10.1002/hep.20839
- †
Potential conflict of interest: DR Averett, SP Fletcher, BM Kerr, LA Bauman, and KR Steffy own stock in and are employed by Anadys Pharmaceuticals. Y Horsmans, T Berg, JP Desager, T Mueller, and E Schott were compensated by Anadys for clinical study services. T Berg and E Schott received a research grant from Anadys. Y Horsmans and T Berg are consultants to Anadys.
Publication History
- Issue published online: 22 AUG 2005
- Article first published online: 22 AUG 2005
- Manuscript Accepted: 24 JUN 2005
- Manuscript Received: 31 JAN 2005
- Abstract
- Article
- References
- Cited By
Cited in:
- CrossRef
This article has been cited by:
- 1, , , , , , , , , , , , , , , , , Biological characterization of a novel class of toll-like receptor 7 agonists designed to have reduced systemic activity, British Journal of Pharmacology, 2012, 166, 2Direct Link:
- 2, , , HIV Infection and TLR Signalling in the Liver, Gastroenterology Research and Practice, 2012, 2012, 1
- 3, , , , , , , , , , , , , PNAS Plus: Lipid-derived nanoparticles for immunostimulatory RNA adjuvant delivery, Proceedings of the National Academy of Sciences, 2012, 109, 14, E797
- 4, , , , , , Preclinical development of TLR ligands as drugs for the treatment of chronic viral infections, Expert Opinion on Drug Discovery, 2012, 1
- 5, , , Prophylactic and therapeutic implications of toll-like receptor ligands, Medicinal Research Reviews, 2012, 32, 2Direct Link:
- 6, , , , The pharmacogenetic background of hepatitis C treatment, Mutation Research/Reviews in Mutation Research, 2012,
- 7, , , The type I interferon response during viral infections: a “SWOT” analysis, Reviews in Medical Virology, 2012, 22, 2Direct Link:
- 8, , , , , , , , , , , , , , Therapy with TLR7 Agonists Induces Lymphopenia: Correlating Pharmacology to Mechanism in a Mouse Model, Journal of Clinical Immunology, 2012,
- 9, , , , Use of modelling and simulation techniques to support decision making on the progression of PF-04878691, a TLR7 agonist being developed for hepatitis C, British Journal of Clinical Pharmacology, 2012, 73, 1Direct Link:
- 10, , , , , , , , , , , , , , , , , , , , , Discovery of a highly potent series of TLR7 agonists, Bioorganic & Medicinal Chemistry Letters, 2011, 21, 19, 5939
- 11, , Hepatitis C Therapy: Other Players in the Game, Clinics in Liver Disease, 2011, 15, 3, 641
- 12, , Mixing the right hepatitis C inhibitor cocktail, Trends in Molecular Medicine, 2011, 17, 1, 34
- 13, , , , , , , , , , , , , , , Randomised clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV, Alimentary Pharmacology & Therapeutics, 2011, 34, 4Direct Link:
- 14, , , Role of Toll-like receptors in liver health and disease, Clinical Science, 2011, 121, 10, 415
- 15, , , Targeting of Toll-like receptors: a decade of progress in combating infectious diseases, The Lancet Infectious Diseases, 2011, 11, 9, 702
- 16, , , , , , , , , , , , , , , , , , The Innate Immune Response, Clinical Outcomes, and Ex Vivo HCV Antiviral Efficacy of a TLR7 Agonist (PF-4878691), Clinical Pharmacology & Therapeutics, 2011, 89, 6, 821
- 17, , Toll-like receptors in acute liver injury and regeneration, International Immunopharmacology, 2011, 11, 10, 1433
- 18, , , Toll-Like Receptors Signaling Contributes to Immunopathogenesis of HBV Infection, Gastroenterology Research and Practice, 2011, 2011, 1
- 19, Development of novel antiviral therapies for hepatitis C virus, Virologica Sinica, 2010, 25, 4, 246
- You have free access to this content20, , , Immunomodulators as adjuvants for vaccines and antimicrobial therapy, Annals of the New York Academy of Sciences, 2010, 1213, 1Direct Link:
- 21, , , Impaired expression and function of toll-like receptor 7 in hepatitis C virus infection in human hepatoma cells, Hepatology, 2010, 51, 1Direct Link:
- 22, , , , , Impaired Toll-like receptor 7 and 9 signaling: from chronic viral infections to cancer, Trends in Immunology, 2010, 31, 10, 391
- 23, , , Innate immunity and chronic immune activation in HCV/HIV-1 co-infection, Clinical Immunology, 2010, 135, 1, 12
- 24
- 25, , , , , , , Quadruplex Genotyping of TLR-8 Polymorphisms in a Single Reaction, Analytical Letters, 2010, 43, 6, 1066
- 26, , , The potential use of Toll-like receptor agonists to restore the dysfunctional immunity induced by hepatitis C virus, Cellular Immunology, 2010, 262, 2, 96
- 27, , , Toll-Like Receptors in the Pathogenesis of Alcoholic Liver Disease, Gastroenterology Research and Practice, 2010, 2010, 1
- 28, , , Toll-like receptor 7 rs179008/Gln11Leu gene variants in chronic hepatitis C virus infection, Journal of Medical Virology, 2010, 82, 11Direct Link:
- 29
- 30, , , , , , Comparison of Rat and Human Responses to Toll-Like Receptor 7 Activation, Journal of Interferon & Cytokine Research, 2009, 29, 2, 113
- 31, , , , Development of novel treatments for hepatitis C, The Lancet Infectious Diseases, 2009, 9, 2, 108
- 32, , Hepatitis C Virus Infection and Immunomodulatory Therapies, Clinics in Liver Disease, 2009, 13, 3, 391
- 33, , , , Hepatitis C virus single-stranded RNA induces innate immunity via Toll-like receptor 7, Journal of Hepatology, 2009, 51, 1, 29
- 34, , , Immunopathogenesis of hepatitis B persistent infection: implications for immunotherapeutic strategies, Clinical Journal of Gastroenterology, 2009, 2, 2, 71
- You have free access to this content35, , , , New developments in the antiviral treatment of hepatitis C, Vox Sanguinis, 2009, 97, 1Direct Link:
- 36, , New therapeutic approaches to hepatitis C virus, Journal of Gastroenterology, 2009, 44, 7, 643
- 37, , , New treatments for hepatitis C: Life cycle lessons, Current Hepatitis Reports, 2009, 6, 2, 75
- 38
- 39, , , , , , , Toll-like receptor activated human and murine hepatic stellate cells are potent regulators of hepatitis C virus replication, Journal of Hepatology, 2009, 51, 6, 1037
- 40, , Translational Mini-Review Series on Vaccines for HIV: Harnessing innate immunity for HIV vaccine development, Clinical & Experimental Immunology, 2009, 157, 2Direct Link:
- 41, , , , , , , , , , Association of TLR7 single nucleotide polymorphisms with chronic HCV-infection and response to interferon-a-based therapy, Journal of Viral Hepatitis, 2008, 15, 1Direct Link:
- 42, , Clinical investigations of Toll-like receptor agonists, Expert Opinion on Investigational Drugs, 2008, 17, 7, 1051
- 43
- 44, Emerging Therapies for Hepatitis C and HIV in Drug Abusers, Journal of Addictive Diseases, 2008, 27, 2, 83
- 45, , Hepatitis C and Innate Immunity: Recent Advances, Clinics in Liver Disease, 2008, 12, 3, 675
- 46, , , , Hepatitis C Virus (HCV): A Review of Immunological Aspects, International Reviews of Immunology, 2008, 27, 6, 497
- 47
- 48, , Promises and challenges for the development ofListeria monocytogenes-based immunotherapies, Expert Review of Vaccines, 2008, 7, 7, 1069
- 49, , Review article: novel therapeutic options for chronic hepatitis C, Alimentary Pharmacology & Therapeutics, 2008, 27, 10Direct Link:
- 50, , , , Toll-like receptor modulation: A novel therapeutic strategy in cardiovascular disease?, Expert Opinion on Therapeutic Targets, 2008, 12, 11, 1329
- 51, , Toll-like receptors and adaptor molecules in liver disease: Update, Hepatology, 2008, 48, 1Direct Link:
- 52, , , , , , , , , , , , , A Toll-like receptor 7 single nucleotide polymorphism protects from advanced inflammation and fibrosis in male patients with chronic HCV-infection, Journal of Hepatology, 2007, 47, 2, 203
- 53, , , Altered innate immunity in chronic hepatitis C infection: Cause or effect?, Hepatology, 2007, 46, 4Direct Link:
- 54, Antiviral therapy: chronic hepatitis C, Journal of Viral Hepatitis, 2007, 14,Direct Link:
- 55, , , , Association Between Toll-Like Receptor Polymorphisms and the Outcome of Liver Transplantation for Chronic Hepatitis C Virus, Transplantation, 2007, 84, 4, 511
- 56, Comment traiter les malades non répondeurs à la bithérapie antivirale C ?, Gastroentérologie Clinique et Biologique, 2007, 31, 3, 317
- 57, Current and future drugs targeting one class of innate immunity receptors: the Toll-like receptors, Drug Discovery Today, 2007, 12, 1-2, 80
- 58, , Current and Future Hepatitis C Therapies, Archives of Medical Research, 2007, 38, 6, 678
- 59, , , , , , , , , , , , , , , , , , Discovery of ANA975: An Oral Prodrug of the TLR-7 Agonist Isatoribine, Nucleosides, Nucleotides and Nucleic Acids, 2007, 26, 6-7, 635
- 60, , , Emerging host cell targets for hepatitis C therapy, Drug Discovery Today, 2007, 12, 5-6, 209
- 61, , , , , , , Oral resiquimod in chronic HCV infection: Safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies, Journal of Hepatology, 2007, 47, 2, 174
- 62, , , , , , Resiquimod and other immune response modifiers as vaccine adjuvants, Expert Review of Vaccines, 2007, 6, 5, 835
- 63, , , Subversion of innate host antiviral strategies by the hepatitis C virus, Archives of Biochemistry and Biophysics, 2007, 462, 2, 254
- 64, , , , , Systems biology and the host response to viral infection, Nature Biotechnology, 2007, 25, 12, 1383
- 65, , , Therapeutic implications of the TLR and VDR partnership, Trends in Molecular Medicine, 2007, 13, 3, 117
- 66, , Toll like receptor 7 and hepatitis C virus infection, Journal of Hepatology, 2007, 47, 2, 165
- 67, , Toll or Toll-Free Adjuvant Path Toward the Optimal Vaccine Development, Journal of Clinical Immunology, 2007, 27, 4, 363
- 68, , Toll-like receptor signaling in HIV-1 infection: a potential target for therapy?, Expert Review of Anti-infective Therapy, 2007, 5, 3, 323
- 69, , Toll-like receptors, RIG-I-like RNA helicases and the antiviral innate immune response, Immunology and Cell Biology, 2007, 85, 6, 435
- 70, , Vaccines and immunotherapies against hepatitis B and hepatitis C viruses, Journal of Viral Hepatitis, 2007, 14,Direct Link:
- 71, , , Antiviral treatment of hepatitis C, Expert Opinion on Pharmacotherapy, 2006, 7, 15, 2025
- 72
- 73, , , , Guanosine analog in the pyrido[2,3-d]pyrimidine ring system As a potential Toll-like receptor agonist, Nucleosides, Nucleotides and Nucleic Acids, 2006, 25, 12, 1391
- 74, , , , , Immune response modifiers: Imiquimod and future drugs for modulating the immune response, Drug Discovery Today: Therapeutic Strategies, 2006, 3, 3, 343
- 75, Innate sensing of self and non-self RNAs by Toll-like receptors, Trends in Molecular Medicine, 2006, 12, 4, 167
- 76, , New therapeutic options for hepatitis C, Current Opinion in Infectious Diseases, 2006, 19, 6, 615
- 77, Nouvelles stratégies thérapeutiques dans l‘hépatite chronique C, Gastroentérologie Clinique et Biologique, 2006, 30, 8-9, 1009
- 78, , Novel approaches for therapy of chronic hepatitis C, Journal of Clinical Virology, 2006, 36, 2, 87
- 79
- 80, , , Pattern recognition receptors: A contemporary view on liver diseases, Hepatology, 2006, 44, 2Direct Link:
- 81, , , , , , Prednisolone Suppresses the Function and Promotes Apoptosis of Plasmacytoid Dendritic Cells, American Journal of Transplantation, 2006, 6, 10Direct Link:
- 82, Resistance of hepatitis C virus to the host antiviral response, Future Virology, 2006, 1, 1, 89
- 83, , Role of MAP Kinase-Dependent Apoptotic Pathway in Innate Immune Responses and Viral Infection, Scandinavian Journal of Immunology, 2006, 63, 6Direct Link:
- 84, , , , Targets of emerging therapies for viral hepatitis B and C, Expert Opinion on Therapeutic Targets, 2006, 10, 6, 833
- 85, , , , The face of future hepatitis C antiviral drug development: Recent biological and virologic advances and their translation to drug development and clinical practice, Journal of Hepatology, 2006, 44, 2, 411
- 86, , , Toll-like receptor modulation in cardiovascular disease: a target for intervention?, Expert Opinion on Investigational Drugs, 2006, 15, 8, 857
- 87